Clinical trials: Gastric Cancer, completed
Oesophageal Carcinoma, Gastric Adenocarcinoma
Determinants of Patient Delay in Doctor Consultation in Oeso-gastric Cancers
This study evaluates the role of socioeconomic and individual factors in the onset of the first symptoms of cancer and the first consultation with a doctor (patient delay) in oeso-gastric cancer.
- Trial name
- DELOGAST (NCT03246516)
- Testing
- Questionnaire
- Where
- 10 sites in France
- Volunteers
- 258 people
- Sponsor
- University Hospital, Lille
Gastric Lesion, Gastritis
Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios
The goal of this clinical trial is to evaluate the diagnostic accuracy of the AI-integrated Capsule Gastroscopy (ACG) system in simulated home-use conditions for detecting upper gastrointestinal (UGI) abnormalities.
- Conditions
- Gastric Lesion, Gastritis, Upper Gastrointestinal Bleeding (UGIB), Gastric Dysplasia
- Trial name
- NCT06848400
- Testing
- AI-integrated Capsule Gastroscopy (ACG) examination, Electronic gastroduodenoscopy (EGD) examination
- Where
- 12 sites in China, Hong Kong and 1 more
- Volunteers
- 482 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Esophageal Cancer
Oxaliplatin and Fluorouracil Plus Radiation Therapy in Treating Patients With Primary Esophageal or Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004257
- Testing
- fluorouracil, oxaliplatin, conventional surgery
- Where
- United States
- Sponsor
- Albany Medical College
Gastric Cancer, Pancreatic Cancer
Evaluating the Potential Usefulness of 18F-AlF-FAPI PET/CT in Patients With Gastrointestinal Tumors and Compared With 18F-FDG PET/CT
To evaluate the potential usefulness of 18F-AlF-FAPI positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in gastrointestinal tumors, and compared with 18F-FDG PET/CT.
- Conditions
- Gastric Cancer, Pancreatic Cancer, Liver Cancer
- Trial name
- NCT05430841
- Testing
- 18F-FDG, 18F-AlF-FAPI PET/CT
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Gastric Cancer
Glycans Bound to Serum Haptoglobin: a Novel Gastric Cancer Tumor Biomarker
The purpose of this study is to evaluate sensitivity and specificity of newly defined tumor biomarker with gastric cancer pts and cancer-free healthy volunteers.
- Trial name
- NCT02848066
- Testing
- Blood sample(10cc) collection
- Where
- South Korea
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Gastric Cancer, Enteral Immunonutrition
Effect of Enteral Immunonutrition on Immune, Inflammatory Markers and Nutritional Status in Patients Undergoing Gastrectomy for Gastric Cancer
Enteral immunonutrition (EIN) has been gaining increasing attention, but data of its immune and anti-inflammatory function in patients undergoing gastrectomy for gastric cancer are poorly investigated.
- Trial name
- NCT03730545
- Testing
- enteral immunonutrition
- Volunteers
- 124 people
- Sponsor
- West China Hospital
Gastric Cancer
Combination Chemotherapy in Treating Patients With Advanced Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004873
- Testing
- cisplatin, docetaxel, epirubicin hydrochloride
- Where
- Switzerland
- Sponsor
- Swiss Cancer Institute
Gastro-intestinal Stromal Tumours
Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)
The objective is to evaluate the efficacy and safety of AB1010 at 7.5 mg/kg/day in the treatment of non pre-treated, inoperable patients with locally advanced/metastatic GIST.
- Trial name
- NCT00998751
- Testing
- oral masitinib
- Where
- France
- Volunteers
- 30 people
- Sponsor
- AB Science
EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast), Malignant Ascites
Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group
The study will be performed to obtain further efficacy and safety data in order to obtain a marketing authorization (pivotal study). In addition, health economic data are to be collected.
- Trial name
- NCT00836654
- Testing
- Catumaxomab (Removab), paracentesis
- Volunteers
- 258 people
- Sponsor
- Neovii Biotech
Stomach Neoplasm
The Origin of Infrapyloric Artery
Infrapyloric artery(IPA) is of great importance for gastric cancer patients. According to previous study, the origin of IPA varies greatly among different studies.
- Trial name
- IPA-Origin (NCT03071237)
- Testing
- Gastrectomy
- Where
- China
- Volunteers
- 429 people
- Sponsor
- Peking University
Gastric Cancer, Complement Component Deficiency
The Predictive Value of Complement C3 in Patients With Advanced Gastric Cancer
This study is designed to investigate whether complement C3 depletion is associated with poor short-term outcomes in postoperative patients with gastric cancer.
- Conditions
- Gastric Cancer, Complement Component Deficiency, Surgery
- Trial name
- NCT02425930
- Testing
- gastrectomy plus D2 lymphadenectomy, S-1+Oxaliplatin
- Where
- China
- Volunteers
- 85 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Colorectal Cancer, Esophageal Cancer
Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin
This research study will examine how often hypersensitivity, or allergic reactions, occur in patients receiving the chemotherapy medication oxaliplatin.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Small Bowel Cancer
- Trial name
- NCT00831571
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Dana-Farber Cancer Institute
Gastric Cancer
Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003298
- Testing
- cisplatin, fluorouracil, leucovorin calcium
- Where
- 30 sites in United States
- Volunteers
- 39 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Gastric Cancer, Esophagus Cancer
KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer
This study will be conducted in two stages: 1) safety validation and 2) dose expansion 1. Safety Validation Cohort: The first portion of the study will preliminarily establish the tolerability of the combination of pembrolizumab…
- Trial name
- NCT03342937
- Testing
- Oxaliplatin+Capecitabine+Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Duke University
Breast Cancer, Gastric Cancer
Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer
This is a first-in-human (FIH), open-label, phase 1 dose-escalation study of KN026 in subjects with HER2 positive advanced breast and Gastric Cancer. The standard "3 + 3" design was used for dose escalation.
- Trial name
- NCT03619681
- Testing
- KN026
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Predictive Cancer Model, Gastric Cancer
A Prospective Clinical Study to Validate a Preoperative Risk Scoring Model for LNM in GC Patients
In our prior research, a risk scoring model for the occurrence of lymph node metastasis in patients who underwent radical gastrectomy for gastric cancer was established.
- Conditions
- Predictive Cancer Model, Gastric Cancer, Lymph Node Metastasis
- Trial name
- NCT06339307
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)
This is a study for participants with advanced gastric or gastroesophageal junction adenocarcinoma who have had tumor progression after first-line treatment with platinum and fluoropyrimidine doublet therapy.
- Trial name
- NCT02370498
- Testing
- pembrolizumab, paclitaxel
- Volunteers
- 592 people
- Sponsor
- Merck Sharp & Dohme LLC
Neuroendocrine Tumor
A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors
Resveratrol has been shown to activate a protein called Notch-1. Signaling of Notch-1 has been shown to prevent tumor cell growth. Resveratrol has also been shown to prevent growth of tumors in mice.
- Trial name
- NCT01476592
- Testing
- Resveratrol
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Wisconsin, Madison
Gastric Cancer
Study to Determine the Antibody Response to 500µg G17DT in Treatment of Patients With Gastric Cancer
This study was designed to investigate the antibody response generated by a 500µg dose of G17DT in patients with gastric cancer.
- Trial name
- GC5 (NCT02450032)
- Testing
- G17DT
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Cancer Advances Inc.
Advanced Solid Tumors
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
The primary objectives of this study are to: Evaluate the safety and tolerability of AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors Determine the recommended phase 2 dose…
- Trial name
- NCT06131398
- Testing
- AMG 355, Pembrolizumab
- Where
- 25 sites in United States, Australia and 9 more
- Volunteers
- 77 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.